Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

303
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
303
Disorders of Leukocytes01:27

Disorders of Leukocytes

1.2K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.2K
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

2.2K
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
2.2K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.3K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.3K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

149
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
149
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.0K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics and clinical course of younger patients with asymptomatic monoclonal gammopathies.

British journal of haematology·2026
Same author

Tiny messengers, big impact: unlocking the power of extracellular vesicles in neonatal health and disease. a systematic review.

Frontiers in immunology·2026
Same author

Small Extracellular Vesicle-Associated microRNA in Cancer: Biology and Applications in Translational Research and Precision Oncology.

Cancers·2026
Same author

Efficacy and Safety of PD-1 Inhibitor-Based Regimens in Patients with Melanoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal of clinical medicine·2026
Same author

Prognostic value of <i>MYD88</i>/<i>CXCR4</i> mutation allele fraction in Waldenström macroglobulinemia using a multiplex ddPCR assay.

HemaSphere·2026
Same author

Safety profile of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma: A systematic review and meta-analysis of proportions from clinical trials.

British journal of haematology·2026

Related Experiment Video

Updated: Oct 13, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K

Metabolic Disorders in Multiple Myeloma.

Maria Gavriatopoulou1, Stavroula A Paschou1, Ioannis Ntanasis-Stathopoulos1

  • 1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.

International Journal of Molecular Sciences
|November 13, 2021
PubMed
Summary

Multiple myeloma cells alter metabolism for survival and growth. Targeting these metabolic pathways may improve cancer therapeutics and immune response in patients with multiple myeloma.

Keywords:
glutaminolysisglycolysismetabolic syndromemetabolismmultiple myeloma

More Related Videos

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

10.6K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.2K

Related Experiment Videos

Last Updated: Oct 13, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K
Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

10.6K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.2K

Area of Science:

  • Hematology
  • Cancer Biology
  • Metabolic Pathways

Background:

  • Multiple myeloma (MM) is a common blood cancer driven by abnormal plasma cell proliferation in bone marrow.
  • Cancer cells, including myeloma cells, reprogram metabolic pathways like glycolysis and glutaminolysis to fuel rapid growth and survival.
  • Metabolic syndrome and inflammation are linked to MM incidence, with metformin and statins showing positive prognostic value.

Purpose of the Study:

  • To review metabolic dysregulation in multiple myeloma.
  • To explore immune system defects associated with MM.
  • To discuss the therapeutic potential of targeting aberrant metabolic pathways.

Main Methods:

  • This is a review article.
  • Literature search on metabolic alterations in multiple myeloma.
  • Analysis of immune system defects and therapeutic strategies.

Main Results:

  • Myeloma cells exhibit significant metabolic reprogramming, primarily involving glycolysis and glutaminolysis.
  • Metabolic disorders in MM can impair immune cell function.
  • Metabolic syndrome and inflammation are associated with increased MM risk.

Conclusions:

  • Metabolic reprogramming is a key feature of multiple myeloma.
  • Targeting metabolic pathways offers a promising strategy to enhance anti-myeloma therapeutics.
  • Further research into metabolic vulnerabilities could lead to novel treatment approaches.